What is the expected contribution from new regions in DXCM's 2021-Q1 guidance 
to take care of them all, what we will do is as organized with as rapid migration as we possibly can. And as far as G6 future plans, we do see a lot of opportunity here, but we really haven't disclosed anything.
Operator
And our next question comes from Steven Lichtman from Oppenheimer. Your line is open.
Steven Lichtman -- Analyst
Great, thanks for taking our questions. I just had a question on your international expansion efforts. What are some of the key countries and focus for you here over the near-term? And are you anticipating any contribution from these new regions in this year's guidance or is that more really more of a driver for 2022? Thank you.
Kevin Sayer -- Chairman, President and Chief Executive Officer
Yeah, I think that will be more of a driver for future years. We've talked about our launch in Japan which Terumo, and that's scheduled to happen in the second half of the year. We got reimbursement in France, as many of you know, so we do expect France to be a bigger part of our business than it has in the past, but the law of large numbers in our businesses, things have gotten so big, they can give us a whole lot that moves the needle when we start. Hence, the discussion we've had about increasing access in our more mature markets and looking at how we follow similar paths in these other geographies with the operating capability we have now there is no sense in going through and selling just the top end of this market, we want to get more aggressive and be more broad. So I think you'll see as we go into these geographies over time, we'll start as we started in the past, but we are going to get more reimbursement and try to get more patients more rapidly.
Operator
And our next question comes from Brandon Vazquez from William Blair. Your line is open.
Brandon Vazquez -- Analyst
Hi, thanks for taking the question. I just wanted to go back to one of the comments made during the prepared remarks and it sounded like there was maybe a little hinting at new connected systems coming this year. So curious if you could talk about those, and specifically what those kinds of products, I'm thinking is there something outside of the regular hardware upgrades that we see maybe somewhere on the software side, that could be a catalyst maybe for growth within maybe some of the TAM expansion opportunities like the Type 2 non-intensives, or gestational diabetes or anything like that. So is there anything we're kind of not thinking out-of-the-box here from the normal hardware that will be important in the coming 12 months or so?
Jereme Sylvain -- Cheif Financial Officer
I don't think that there is anything that you guys are missing in terms of the prepared remarks and speaking to some of those systems. The one thing that we certainly are excited about, has to be the Omnipod 5 product in the back half of the year, and we'll let Insulet speak to the exact timing of when we're ready to put that product into the marketplace, but having connectivity into a product like that is something that we're very excited about and believe that they'll have success with and will have success with as well.
I think with respect to the whole Type 2 population and the opportunity there, we couldn't be more bullish on the opportunity that sits in front of us, and I think by the day we learn more-and-more of that increases that bullishness for us in the confidence that there's going to be some real opportunity there to create value coming from it, and you're going to see a study a little bit later this year, mid-year at some of the mid-year society meetings, that's going to start to really lay out the benefit of using CGM relative to BGM in this Type 2 population, particularly the non-intensive population that just demonstrates the sort of impact we can have on patients that are on basal only and that's a 4 million patient population in the U.S.
So I think that sort of data starts to really accumulate in favor of opening up a whole another market segment that doubles the existing core U.S. intensive market today that we're very excited about. So you
to take care of them all, what we will do is as organized with as rapid migration as we possibly can. And as far as G6 future plans, we do see a lot of opportunity here, but we really haven't disclosed anything.
Operator
And our next question comes from Steven Lichtman from Oppenheimer. Your line is open.
Steven Lichtman -- Analyst
Great, thanks for taking our questions. I just had a question on your international expansion efforts. What are some of the key countries and focus for you here over the near-term? And are you anticipating any contribution from these new regions in this year's guidance or is that more really more of a driver for 2022? Thank you.
Kevin Sayer -- Chairman, President and Chief Executive Officer
Yeah, I think that will be more of a driver for future years. We've talked about our launch in Japan which Terumo, and that's scheduled to happen in the second half of the year. We got reimbursement in France, as many of you know, so we do expect France to be a bigger part of our business than it has in the past, but the law of large numbers in our businesses, things have gotten so big, they can give us a whole lot that moves the needle when we start. Hence, the discussion we've had about increasing access in our more mature markets and looking at how we follow similar paths in these other geographies with the operating capability we have now there is no sense in going through and selling just the top end of this market, we want to get more aggressive and be more broad. So I think you'll see as we go into these geographies over time, we'll start as we started in the past, but we are going to get more reimbursement and try to get more patients more rapidly.
Operator
And our next question comes from Brandon Vazquez from William Blair. Your line is open.
Brandon Vazquez -- Analyst
 Hi, thanks for taking the question. I just wanted to go back to one of the comments made during the prepared remarks and it sounded like there was maybe a little hinting at new connected systems coming this year. So curious if you could talk about those, and specifically what those kinds of products, I'm thinking is there something outside of the regular hardware upgrades that we see maybe somewhere on the software side, that could be a catalyst maybe for growth within maybe some of the TAM expansion opportunities like the Type 2 non-intensives, or gestational diabetes or anything like that. So is there anything we're kind of not thinking out-of-the-box here from the normal hardware that will be important in the coming 12 months or so?
Jereme Sylvain -- Cheif Financial Officer
I don't think that there is anything that you guys are missing in terms of the prepared remarks and speaking to some of those systems. The one thing that we certainly are excited about, has to be the Omnipod 5 product in the back half of the year, and we'll let Insulet speak to the exact timing of when we're ready to put that product into the marketplace, but having connectivity into a product like that is something that we're very excited about and believe that they'll have success with and will have success with as well.
I think with respect to the whole Type 2 population and the opportunity there, we couldn't be more bullish on the opportunity that sits in front of us, and I think by the day we learn more-and-more of that increases that bullishness for us in the confidence that there's going to be some real opportunity there to create value coming from it, and you're going to see a study a little bit later this year, mid-year at some of the mid-year society meetings, that's going to start to really lay out the benefit of using CGM relative to BGM in this Type 2 population, particularly the non-intensive population that just demonstrates the sort of impact we can have on patients that are on basal only and that's a 4 million patient population in the U.S.
So I think that sort of data starts to really accumulate in favor of opening up a whole another market segment that doubles the existing core U.S. intensive market today that we're very excited about. So you